NEW YORK (GenomeWeb News) — Algonomics has taken in €500,000 ($670,000) in a second closing of a financing round to net a total of €2 million ($2.7 million), the company said today.
 
The immunoprofiling company plans to use the funding to continue developing an in vitro screening platform, called Epibase, to complement its existing screening products and services.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.